Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Jun 02, 2026

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

May 14, 2026

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

See More Press Releases

The Conversation (0)

Alert Options

No alert set

INN Article Notification

Instant Daily Weekly

Alert Option

You will be notified when this event occurs. No additional settings needed.